MH-SVM25 [SVM-25] (ATCC® HB-8871)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type:: hybridoma: B lymphocyte  / 

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Applications
The antibody reacts specifically with HIV-1 gp41.
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
Animals were immunized with lysates of purified HIV-1.
Spleen cells were fused with NS-1 myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against HTLV-III (HIV-1, human immunodeficiency virus - 1) gp41 (41000 dalton glycoprotein)
Cellular Products
immunoglobulin; monoclonal antibody; against HTLV-III (HIV-1, human immunodeficiency virus - 1) gp41 (41000 dalton glycoprotein)
Comments
Animals were immunized with lysates of purified HIV-1.
Spleen cells were fused with NS-1 myeloma cells.
The antibody reacts specifically with HIV-1 gp41.
Complete Growth Medium Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 2 mM L-glutamine, and 1 mM sodium pyruvate, 80%; fetal bovine serum, 20%
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Isotype IgG1; kappa light chain
Name of Depositor Akzo Nobel N.V.
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Sarngadharan MG, et al. Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production. US Patent 4,843,011 dated Jun 27 1989

Basic Documentation
References

Sarngadharan MG, et al. Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production. US Patent 4,843,011 dated Jun 27 1989